O6-[(2″,3″-O-Isopropylidene-5″-O-tbutyldimethylsilyl)pentyl]-5′-O-tbutyldiphenylsilyl-2′,3′-O-isopropylideneinosine

Abstract

Cyclic adenosine diphosphate ribose (cADPR) is a cyclic nucleotide involved in the Ca2+ homeostasis. In its structure, the northern ribose, bonded to adenosine through an N1 glycosidic bond, is connected to the southern ribose through a pyrophosphate bridge. Due to the chemical instability at the N1 glycosidic bond, new bioactive cADPR derivatives have been synthesized. One of the most interesting analogues is the cyclic inosine diphosphate ribose (cIDPR), in which the hypoxanthine replaced adenosine. The efforts for synthesizing new linear and cyclic northern ribose modified cIDPR analogues led us to study in detail the inosine N1 alkylation reaction. In the last few years, we have produced new flexible cIDPR analogues, where the northern ribose has been replaced by alkyl chains. With the aim to obtain the closest flexible cIDPR analogue, we have attached to the inosine N1 position a 2″,3″-dihydroxypentyl chain, possessing the two OH groups in a ribose-like fashion. The inosine alkylation reaction afforded also the O6-alkylated regioisomer, which could be a useful intermediate for the construction of new kinds of cADPR mimics.

Molecular docking, drug-likeness and DFT study of some modified tetrahydrocurcumins as potential anticancer agents

“…They reported that five compounds of newly synthesized have IC 50 values less than 5.95 µM. In our continuous attempts to develop novel potent bioactive agents ( Abdel-Jalil et al, 2015 , El-ajaily et al, 2019 , El-Barasi et al, 2020 , Eleya et al, 2011 , Hussain et al, 2008 , Ibad et al, 2011 , Kamel et al, 2022a , Kamel et al, 2022b , Mahal, 2015a , Mahal et al, 2010 , Mahal et al, 2011 , Mahal et al, 2015b , Mahal et al, 2015c , Mahal et al, 2019 , Mahal et al, 2021 , Marzano et al, 2022 , Mohapatra et al, 2021 , Salman et al, 2011 , Salman et al, 2020 , Salman et al, 2022 , Yang et al, 2017 , Yang et al, 2018 , Zinad et al, 2020a , Zinad et al, 2020b , Zinad et al, 2020c , Zinad et al, 2020d , Zinad et al, 2021a , Zinad et al, 2021b , Zinad et al, 2022 , Zinad et al, 2023a , Zinad et al, 2023b ), we aim at this study to investigate the molecular docking and DFT calculation of potent anticancer agents of tetrahydrocurcumin.…”